Ipamorelin
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic five-amino-acid peptide that selectively prompts pulse-like growth hormone release, marketed for anti-aging, muscle, and recovery. Selective GH release and short-term safety have moderate support, but fat-loss and bone claims rest mostly on animal data or theory, so the human case is weak. Only three published human studies exist and it stalled at Phase II. Not an approved US drug; sold mostly as research-grade material of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(7)
Selective GH release
MediumRaises GH, with ACTH and cortisol responses similar to GHRH in animal studies.
Body composition
SpeculativeLean-mass and fat-loss effects are inferred from animal growth data and the GH/IGF-1 mechanism.
Bone growth/density
LowDose-dependent bone growth in rats, reflecting larger bone size rather than higher density.
Evidence limits
- Evidence Level
- Limited Clinical
PK study in healthy males (1999), Phase II POC for postop ileus (n=114, 2014), Phase II dose-finding bowel resection (n=320). POC well-tolerated but missed primary endpoint (p=0.15). Developed by Novo Nordisk, later licensed to Helsinn, did not advance past Phase II.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Pituitary tumors
AbsoluteDirectly stimulates the pituitary. Contraindicated with pituitary adenomas.
Active cancer
HighGrowth hormone elevation may promote tumor growth through IGF-1 pathway.
Diabetic retinopathy
HighGH/IGF-1 elevation can worsen diabetic retinopathy.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Limited human clinical data (3 published studies)
ModerateLong-term safety data lacking
ModerateDid not advance past Phase II clinical trials
HighPotential GH-related effects: water retention, joint discomfort
ModerateTheoretical concerns with prolonged GH/IGF-1 elevation and cancer risk
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.